Global Airway Stents Market Revenue to Fall 13 Percent This Year

Nearly 13 percent of revenue from airway stents will be lost in 2020 due to COVID-19, as many surgical procedures have been postponed, according to GlobalData, a worldwide data and analytics company. Before the pandemic was declared, GlobalData had calculated a global market size of $51.3 million for airway stents, compared to $46.1 million when accounting for the impact of COVID-19.
 
Given that Boston Scientific Corp. is the market leader for airway stent sales, this company will experience the most revenue lost during the COVID-19 pandemic. Other companies such as Atrium Medical Systems Inc. and Merit Medical Systems Inc. will also experience the effects of sales declines. Therefore, it is unlikely that these companies will experience the level of growth that was predicted at the start of the year. 
 
Eric Chapman, a medical devices analyst at GlobalData, said: “In Q1 2020, many procedures were postponed from around mid-March (two out of 12 weeks) and this two-week period had a significant impact on the overall sales of airways stents. By analysing GlobalData’s proprietary U.S. hospital purchasing dataset, it has been determined that year-on-year (YOY) sales for airway stents declined by 18.4 percent in Q1 2020. 
 
“By Q2 2020, sales had reached a low point with year-over-year revenue down 38.8 percent, as the number new COVID-19 cases had reached a peak and many procedures had been cancelled or postponed.”
 
In Q3 2020, GlobalData estimates that the market will begin to experience a gradual recovery as procedures are rescheduled. Initially, GlobalData estimated an overall reduction of 15 percent of revenue for the quarter, compared to predictions before the COVID-19 outbreak; however, a resurgence of new COVID-19 cases might result in further delays in procedures. 
 
Chapman added: “By Q4 2020, GlobalData anticipates the start of a ‘surge period’ for the airway stents market, to make up for sales that were postponed earlier in the year. However, this surge will not be enough to offset revenue losses until the end of 2021 or early 2022. It is possible that these companies will reduce the price of their products to stimulate sales, as has been seen in other markets.”
 
* Global estimates include the markets for 39 countries.